TICKERNOMICS Sign up
Last Update: 2023-12-23 05:58:26
Karuna Therapeutics Inc. ( KRTX ) https://www.karunatx.com
215.19USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
KRTX
9.38%
SPY
30.72%
KRTX
106.46%
SPY
112.82%
KRTX
0.00%
SPY
201.04%
KRTX
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
8282.94
7143.55
0.18
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-21.54
733.59
6.26
-3.00
0.00
-15.92
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-18334.40
100.00
-6196.92
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
3.86
-178.94
-61.27
0.00
Other Earnings and Cash Flow Stats:
Karuna Therapeutics Inc. ( KRTX ) Net Income TTM ($MM) is -350.46
Karuna Therapeutics Inc. ( KRTX ) Operating Income TTM ($MM) is -411.31
Karuna Therapeutics Inc. ( KRTX ) Owners' Earnings Annual ($MM) is 0.00
Karuna Therapeutics Inc. ( KRTX ) Current Price to Owners' Earnings ratio is 0.00
Karuna Therapeutics Inc. ( KRTX ) EBITDA TTM ($MM) is -409.92
Karuna Therapeutics Inc. ( KRTX ) EBITDA Margin is -6196.92%
Capital Allocation:
Karuna Therapeutics Inc. ( KRTX ) has paid 0.00 dividends per share and bought back -5.340033 million shares in the past 12 months
Karuna Therapeutics Inc. ( KRTX ) has increased its debt by 9.723 million USD in the last 12 months
Capital Structure:
Karuna Therapeutics Inc. ( KRTX ) Interest-bearing Debt ($MM) as of last quarter is 15
Karuna Therapeutics Inc. ( KRTX ) Annual Working Capital Investments ($MM) are 266
Karuna Therapeutics Inc. ( KRTX ) Book Value ($MM) as of last quarter is 1322
Karuna Therapeutics Inc. ( KRTX ) Debt/Capital as of last quarter is 1%
Other Balance Sheet Stats:
Karuna Therapeutics Inc. ( KRTX ) has 184 million in cash on hand as of last quarter
Karuna Therapeutics Inc. ( KRTX ) has 48 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Karuna Therapeutics Inc. ( KRTX ) has 37 common shares outstanding as of last quarter
Karuna Therapeutics Inc. ( KRTX ) has 0 million USD of preferred stock value
Academic Scores:
Karuna Therapeutics Inc. ( KRTX ) Altman Z-Score is 78.34 as of last quarter
Karuna Therapeutics Inc. ( KRTX ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Karuna Therapeutics Inc. ( KRTX ) largest shareholder is State Street Corporation owning 928970 shares at 199.91 ($MM) value
Stephen K Brannan(an insider) Sold 10000 shares of Karuna Therapeutics Inc. ( KRTX ) for the amount of $2023700.00 on 2023-12-08
4.88% of Karuna Therapeutics Inc. ( KRTX ) is held by insiders, and 101.81% is held by institutions
Karuna Therapeutics Inc. ( KRTX ) went public on 2019-06-28
Other Karuna Therapeutics Inc. ( KRTX ) financial metrics:
FCF:-244.03
Unlevered Free Cash Flow:-191.76
EPS:-12.64
Operating Margin:-18334.40
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-36.03
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Karuna Therapeutics Inc. ( KRTX ) :
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of mood and anxiety disorders. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.